Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
NCT05333458 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is recruiting participants. It studies Atezolizumab and Selinexor in Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma and 3 more conditions. The registry lists an enrollment of 27 participants at 13 sites in 1 country. The registry lists a start date of 29 Aug 2022 and a primary completion date of 1 May 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05333458 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | National Cancer Institute (NCI) |
| Enrollment | 27 |
| Registered sites | 13 |
| Countries | 1 |
| Conditions | Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma and Unresectable Alveolar Soft Part Sarcoma |
| Drugs | Atezolizumab and Selinexor |
| Start | 29 Aug 2022 |
| Primary completion | 1 May 2027 |
| Study completion | 1 May 2027 |
| Last update posted | 18 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- A P Chen
National Cancer Institute LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Keck Medicine of Usc Koreatown
Los Angeles
Mark AgulnikRecruiting - Los Angeles General Medical Center
Los Angeles
Mark AgulnikRecruiting - Usc / Norris Comprehensive Cancer Center
Los Angeles
Mark AgulnikRecruiting
- Smilow Cancer Hospital Care Center at Saint Francis
Hartford
Philippos Apolinario CostaRecruiting - Yale University
New Haven
Philippos Apolinario CostaRecruiting - Smilow Cancer Hospital Care Center-Trumbull
Trumbull
Philippos Apolinario CostaRecruiting
- Medstar Georgetown University Hospital
Washington D.C.
Benjamin A. WeinbergRecruiting
- National Cancer Institute Developmental Therapeutics Clinic
Bethesda
A P. ChenRecruiting - National Institutes of Health Clinical Center
Bethesda
Active, not recruiting
- Ohio State University Comprehensive Cancer Center
Columbus
David A. LiebnerRecruiting
- University of Oklahoma Health Sciences Center
Oklahoma City
Minh PhanRecruiting
- Upmc Hillman Cancer Center
Pittsburgh
Melissa A. BurgessRecruiting
- Ut Md Anderson Cancer Center
Houston
Anthony P. ConleyRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05333458
Each answer restates registry values shown on this page.
What is NCT05333458?
NCT05333458 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Atezolizumab and Selinexor in Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma and 3 more conditions.
Is NCT05333458 recruiting?
As of 21 Nov 2026, it is recruiting participants. 12 of its 13 sites list their own status as recruiting.
Who leads NCT05333458?
The registry names A P Chen (principal investigator, National Cancer Institute LAO) as the overall official.
Where does NCT05333458 run?
The registry lists 13 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05333458 study?
The registered drug and biological interventions are Atezolizumab and Selinexor.
When is NCT05333458 expected to complete?
The registry lists a primary completion date of 1 May 2027 and a study completion date of 1 May 2027. The sponsor last updated the record on 18 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.